Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 57Kidney Neoplasms 16Neoplasms 15Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma 6Glioblastoma 5Clear-cell metastatic renal cell carcinoma 5Lung Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Ovarian Neoplasms 3Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraganglioma 2Liver Neoplasms 2Kidney Diseases 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Axitinib × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡